Table 1.

Assessment Tools for Pediatric Neuropathic Pain

Tool	Proposed Target Population			Advantages/Disadvantages
I. Screening Tools
1. Pediatric-modified Total Neuropathy Score 3 sets of symptom questions 5 physical examination signs		Children aged 5–18 years with chemotherapy-induced peripheral neuropathy	Good reliability and internal consistency Good for screening and assessment Not as sensitive to change over time Clinical significance of scores is unclear
II. Assessment Tools
2. Adolescent Pediatric Pain Tool Body outline Word graphic rating scale List of 67 symptom descriptors		Children aged 8–17 years with acute pain (hospitalized or not)	Good validity, reliable in a variety of pain conditions Quickly completed Multidimensional approach to pain Not well studied in chronic or complex pain
3. Pediatric Pain Questionnaire 10-cm Visual Analog Scale 46 symptom descriptors Pain location		Children aged 5–18 years Primarily used in patients with juvenile rheumatoid arthritis and sickle-cell anemia	Derived from the well-studied McGill Pain Questionnaire Well-established evidence of validity Takes 15 min to complete
4. Abu-Saad Pediatric Pain Assessment Tool 10-cm Visual Analog Scale 32 symptom descriptors		Children aged 5–17 years with disease-related pain or undergoing surgery	Assesses multiple aspects of pain, including triggers and medication type/amount Good internal consistency Less supportive evidence than for other tools

^*Reproduced with permission from [34] - The assessment tools were validated for pain in children; they may be helpful for NP because they assess the pain characteristics